🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

HSCT in Monogenic IBD: Game Changer? New 10-year study (2012–2022) shows: 🔹 100% survival post-HSCT 🔹 92% achieved medication-free remission 🔹 60% with prior ostomy had successful re-anastomosis 👉 HSCT is curative & lifesaving in IBD Satya Prakash Yadav pubmed.ncbi.nlm.nih.gov/40378986/

Anaerobic Antibiotics & GVHD Risk in HSCT Meta-analysis (n=2169) suggests: ⚠️ ↑ Acute GVHD risk with antibiotics having anaerobic coverage 🔹 RR: 1.33 (95% CI: 1.17–1.51) ⚠️ ↑ GVHD-related mortality 🔹 RR: 1.65 (95% CI: 0.94–2.91) pubmed.ncbi.nlm.nih.gov/40298411/

Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collabration 🔬 Multinational data (Japan + US, n > 4,000) ▶️ AML: Adding AraC/VP16 to CY/TBI ⬇️ OS (HR 1.46 & 1.39) ▶️ ALL: CY/TBI+VP16 ⬇️ relapse (HR 0.74) but ↑

Letermovir in Pediatric Allo-HSCT 📍 Italy | n=287 | 2014–2023 CMV Reactivation @ 3 months: ⚠️ No prophylaxis: 29.5% ✅ Primary Letermovir: 3.7% (p=0.0029) ✅ Secondary Letermovir: 0% vs 34.7% (no prophylaxis) ✅ Letermovir = safe, effective 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM

New entity Calicheamicin Syndrome .? 🔬 Inotuzumab-induced liver toxicity ✅ Elevated LFTs ✅ Thrombocytopenia ✅ Sinusoidal congestion WITHOUT SOS pubmed.ncbi.nlm.nih.gov/40296727/ Satya Prakash Yadav 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM

Over 57 Cr people watching IPL on JioCinema — that's more than the entire population of over 100 countries! 🤯 Only a few nations like India, China, and the US even come close. This isn’t just cricket, it’s a global phenomenon! 🏏🔥 #IPL2025 #DigitalIndia"

Tears in his eyes, This isn’t just about the game — it’s about the years of passion, grind, and unwavering belief. The journey, the struggle, the joy — that's what makes it beautiful. 🏏❤️ #CricketEmotion #ViratKohli #IPL2025 #IPLFinal

7-year-old boy Presents with: Fatigue, pallor, and easy bruising Hepatosplenomegaly, no lymphadenopathy Pancytopenia, ESR ↑, Cr 5.8 mg/dL Bone Marrow Biopsy Showing What is the diagnosis And treatment of choice? #ashimagebank 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM

Post-allo-SCT outcomes in Hematologic Malignancies Following Pembrolizumab Therapy Median time to SCT: 4.6 mo 6-mo grade II–IV aGVHD: 41% 6-mo grade III–IV aGVHD: 20% 1-yr chronic GVHD: 19% 📈 40-mo PFS: 56.8% 📈 40-mo OS: 76.5% TRM: 17%, Relapse: 27% 🧵 For cHL subgroup:

#BLOCKURDATE 10th Midterm PHO CME 2025 PGICH #Noida Learn more about #PedALL & #thalassemia #Registrations open Dr Manas Kalra Nita Radhakrishnan Shruti Kakkar Satya Prakash Yadav Silky Jain Shweta Bansal Dr Neha Rastogi Anand KC Pritam Singha Roy MD, DM Dr Gaurav Kharya

Thiotepa Versus Non-Thiotepa Based Conditioning in Children Undergoing Haploidentical Stem Cell Transplant with Post Transplant Cyclophosphamide for Leukemia ⁦Dr.Rachit Khandelwal, MD⁩ ⁦Dr Neha Rastogi⁩ ⁦dr dhwanee thakkar⁩ ⁦Medanta⁩ researchgate.net/publication/38…

Haploidentical HSCT in Pediatric Transfusion-Dependent Thalassemia: A Systematic Review and Meta-Analysis 10-study of haploidentical HSCT in 356 children • Overall survival: 92.4% • Thalassemia-free survival: 84.5% • Graft failure: 8.1% • Transplant-related mortality:

Marstacimab Prophylaxis in Hemophilia A/B Without Inhibitors: Results from the Phase 3 BASIS Trial 🔹 Weekly SC 150mg 🔹 ↓ ABR:  • From 39.86 → 3.2 (on-demand group)  • From 7.9 → 3.4 (routine prophylaxis) 🔹 ABR ratio: 0.08 (p < 0.0001) 📌 Phase 3 BASIS trial

Impact of Cytomegalovirus Reactivation Following Allogeneic HSCT on the Relapse of Acute Leukemia - 1258 AML/ALL patients post-HCT (2000–2020), CMV reactivation (in 61.6%) was linked to: ✅ ↓ Relapse risk (HR 0.713, p = .001) ✅ ↑ Event-free survival (HR 0.743, p = .001) ❌

Such a thriller at Lord’s! Final day. Last wicket. Run chase. India vs England — Test cricket at its absolute best. 🏏🔥 #INDvENG #Lords #TestCricket

Bone Marrow Transplantation for Sickle Cell Disease: A Study of Parents' Decisions: New England Journal of Medicine: Vol 325, No 19 1991 NEJM study found that 54% of parents of kids with sickle cell disease were willing to accept a 15% mortality risk from bone marrow

ChatGPT version of super docs 😅😅

#MidtermPHOCON2025 #ALL #PHOCON4all How to minimise ALL tt toxicity Dr Manas Kalra Nita Radhakrishnan Satya Prakash Yadav Dr Neha Rastogi Dr.Rachit Khandelwal, MD Archana M V Bharat Agarwal Badira Cheriyalinkal Parambil Silky Jain Shruti Kakkar Dr Sunil Bhat Dr Gaurav Kharya Vinay Munikoty Venkatesh